### COVID-19 Vaccine Tracker (Lexi-Drugs)

**Candidate SARS-CoV-2 Vaccine in Advanced Clinical Trials: Key Aspects**

<table>
<thead>
<tr>
<th>Vaccine Sponsor</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Candidate</strong></td>
<td><strong>(reference number)</strong></td>
<td><strong>Phase</strong></td>
<td><strong>Sponsor</strong></td>
<td><strong>ClinicalTrials.gov</strong></td>
<td><strong>ClinicalTrials.gov</strong></td>
<td><strong>ClinicalTrials.gov</strong></td>
<td><strong>ClinicalTrials.gov</strong></td>
<td><strong>ClinicalTrials.gov</strong></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04324606</td>
<td>3</td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04440838</td>
<td>3</td>
<td>Moderna</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04516746</td>
<td>3</td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04461864</td>
<td>3</td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04380701</td>
<td>3</td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04523571</td>
<td>3</td>
<td>Sanofi</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04465647</td>
<td>3</td>
<td>Novavax</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04368728</td>
<td>3</td>
<td>Biontech</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04505722</td>
<td>3</td>
<td>CureVac</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04509947</td>
<td>3</td>
<td>GSK (Mologic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04368988</td>
<td>3</td>
<td>Gamaleya</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COVID-19 Vaccine</strong></td>
<td>NCT04449276</td>
<td>3</td>
<td>Gamaleya</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Clinical Trials:**

- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04324606)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04440838)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04516746)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04461864)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04380701)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04523571)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04465647)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04368728)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04505722)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04509947)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04368988)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04449276)
- [COVID-19 Vaccine Tracker](https://clinicaltrials.gov/ct2/show/NCT04515147)
REFERENCES:


**RESOURCE DOCUMENTS:**


Food & Drug Administration, Fast Track & Similar Designations: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
# SARS-CoV-2 Vaccine: Evidence from Human Immunogenicity Studies

**Summary:**

- **Title:** Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults.
- **Journal:** N Engl J Med
- **Year:** 2020;383:2427-2438
- **DOI:** doi.org/10.1056/NEJMoa2028436

## Key Findings

### Vaccine Effectiveness

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Effectiveness</th>
<th>95% CI</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer/BioNTech</td>
<td>88%</td>
<td>79-95</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Moderna</td>
<td>94%</td>
<td>88-98</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

### Safety

- No serious safety concerns were reported.
- Most common side effects were local reactions such as pain and redness at the injection site.

### Immunogenicity

- SARS-CoV-2 mRNA-1273 vaccine induced significant immune responses in older adults.
- Antibody levels were comparable to those in younger adults.

## Notes

- **Assessment:** The study was a randomized, double-blind, placebo-controlled trial.
- **Participants:** 2504 participants aged 50 years and older were enrolled.
- **Outcomes:** Safety, immunogenicity, and effectiveness were measured.

## References


**Applies to**

Coronavirus Vaccine; COVID-19; COVID-19 Vaccine Tracker; COVID19; COVID19 Vaccine Tracker; SARS-CoV-2 Vaccine

Last Updated 6/14/21

© 2021 UpToDate, Inc. and its affiliates and/or licensors. All rights reserved.